Patents by Inventor Lydia Lynch

Lydia Lynch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeting gamma-delta T Cells in Obesity and Cachexia
    Publication number: 20230158112
    Abstract: Methods of promoting or inhibiting weight loss by modulating activity or levels of ?? T cells.
    Type: Application
    Filed: September 1, 2022
    Publication date: May 25, 2023
    Inventors: Michael Brenner, Lydia Lynch, Ayano Kohlgruber
  • Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
    Patent number: 11097005
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: August 24, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • TARGETING GAMMA-DELTA T CELLS IN OBESITY AND CACHEXIA
    Publication number: 20200188482
    Abstract: Methods of promoting or inhibiting weight loss by modulating activity levels of ?? T cells.
    Type: Application
    Filed: April 30, 2018
    Publication date: June 18, 2020
    Inventors: Michael Brenner, Lydia Lynch, Ayano Kohlgruber
  • METHODS AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS
    Publication number: 20180296671
    Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.
    Type: Application
    Filed: March 5, 2018
    Publication date: October 18, 2018
    Inventors: Mark A. EXLEY, Lydia LYNCH, Donal O'SHEA, Cliona O'FARRELLY, Steven P. BALK
  • Methods and compositions for treatment of metabolic disorders
    Patent number: 9907848
    Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: March 6, 2018
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Mark A. Exley, Lydia Lynch, Donal O'Shea, Cliona O'Farrelly, Steven P. Balk
  • USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS
    Publication number: 20170360934
    Abstract: Provided herein are methods and pharmaceutical compositions for the treatment of obesity-associated conditions using cadherin-11 antagonists.
    Type: Application
    Filed: December 15, 2015
    Publication date: December 21, 2017
    Applicant: The Brigham and Women's Hospital, Inc.
    Inventors: Michael B. Brenner, Sook Kyung Chang, Lydia Lynch
  • METHODS AND COMPOSITIONS FOR TREATMENT OF METABOLIC DISORDERS
    Publication number: 20140079771
    Abstract: The present invention relates to the discovery that increases in invariant NKT cell (iNKT) number and/or activity can reduce the incidence or severity of metabolic disorders such as obesity and diabetes. The invention accordingly features methods, kits, and compositions for the treatment of such metabolic disorders by administration of a composition capable of increasing iNKT activity.
    Type: Application
    Filed: September 9, 2013
    Publication date: March 20, 2014
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Mark A. EXLEY, Lydia Lynch, Donal O'Shea, Cliona O'Farrelly, Steven P. Balk